- Home
- KITT vs MBRX Comparison
KITT vs MBRX Comparison
Compare KITT & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KITT
- MBRX
- Stock Information
- Founded
- KITT 2014
- MBRX 2015
- Country
- KITT United States
- MBRX United States
- Employees
- KITT N/A
- MBRX N/A
- Industry
- KITT Industrial Machinery/Components
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- KITT Industrials
- MBRX Health Care
- Exchange
- KITT Nasdaq
- MBRX Nasdaq
- Market Cap
- KITT 38.8M
- MBRX 12.9M
- IPO Year
- KITT N/A
- MBRX 2016
- Fundamental
- Price
- KITT $0.99
- MBRX $0.63
- Analyst Decision
- KITT
- MBRX Strong Buy
- Analyst Count
- KITT 0
- MBRX 3
- Target Price
- KITT N/A
- MBRX $5.33
- AVG Volume (30 Days)
- KITT 1.1M
- MBRX 12.4M
- Earning Date
- KITT 08-12-2025
- MBRX 08-13-2025
- Dividend Yield
- KITT N/A
- MBRX N/A
- EPS Growth
- KITT N/A
- MBRX N/A
- EPS
- KITT N/A
- MBRX N/A
- Revenue
- KITT $1,508,374.00
- MBRX N/A
- Revenue This Year
- KITT $2,936.06
- MBRX N/A
- Revenue Next Year
- KITT N/A
- MBRX N/A
- P/E Ratio
- KITT N/A
- MBRX N/A
- Revenue Growth
- KITT N/A
- MBRX N/A
- 52 Week Low
- KITT $0.82
- MBRX $0.25
- 52 Week High
- KITT $6.13
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- KITT 51.99
- MBRX 57.45
- Support Level
- KITT $0.95
- MBRX $0.50
- Resistance Level
- KITT $1.09
- MBRX $0.70
- Average True Range (ATR)
- KITT 0.06
- MBRX 0.09
- MACD
- KITT 0.01
- MBRX 0.05
- Stochastic Oscillator
- KITT 52.29
- MBRX 78.36
About KITT Nauticus Robotics Inc.
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.